R&D | April 22, 2026
Leinco and CellCarta team up to power next-gen proteomics for cancer and targeted therapies
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
The session created a platform for meaningful discussions on the challenges of the disease and the importance of timely intervention
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
Access to genomic testing, not therapy cost, is the biggest challenge
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
Subscribe To Our Newsletter & Stay Updated
